INOVIO to Report First Quarter Financial Results on May 13, 2026
Rhea-AI Summary
INOVIO (NASDAQ:INO) will release its first quarter 2026 financial results after market close on May 13, 2026. A live conference call and webcast will follow at 4:30 p.m. ET for a financial review and general business update, with a listen-only format and live Q&A.
The webcast will be archived and available for replay for 90 days at the company's investor events page.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – INO
On the day this news was published, INO gained 3.64%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INO was flat while several biotech peers in the same sector showed positive price changes, and no peers appeared in the momentum scanner, pointing to stock-specific positioning rather than a sector-wide move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings date notice | Neutral | +3.6% | Announced timing of Q4 and full-year 2025 results and related webcast. |
Limited history for ‘earnings date’ headlines; the prior notice of results was followed by a modest positive move.
Over recent months INOVIO has combined financing activity, regulatory milestones, and scientific visibility. In March 2026, it reported 2025 results and highlighted BLA acceptance for INO-3107 with a PDUFA date of October 30, 2026, alongside reduced operating expenses and a narrowed $84.9M net loss. An April $17.5M public offering pressured the stock. Today’s announcement simply schedules Q1 2026 results for May 13, 2026, similar in structure to the prior earnings-date notice.
Historical Comparison
In the past 6 months, INO issued 1 prior ‘earnings date’ notice, which saw a 3.57% move. Any reaction to this new Q1 2026 date can be compared to that baseline.
Earnings-date communications have followed a consistent pattern: announcing the release date, after-hours timing, and a 4:30 p.m. ET webcast with a 90-day replay.
Market Pulse Summary
This announcement sets expectations for Q1 2026 results on May 13, 2026 with a 4:30 p.m. ET webcast and a 90-day replay. Context includes recent 2025 results featuring a narrowed $84.9M net loss, cash of $58.5M, and a PDUFA date of October 30, 2026 for INO-3107, followed by a $17.5M public offering. Investors may focus on Q1 cash burn, pipeline progress, and any updates to regulatory timelines.
AI-generated analysis. Not financial advice.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com
Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-financial-results-on-may-13-2026-302760436.html
SOURCE INOVIO Pharmaceuticals, Inc.